Novo Nordisk: A Textbook Value Trap

The author reiterates a strong sell on Novo Nordisk, arguing that U.S. pricing pressure on GLP‑1 therapies is capping revenue and profitability despite a 13x forward P/E. Key risks include competitive pricing from the TrumpRx platform (~$245/month by 2027) and future cheaper oral pills (~$150/month), with Street forecasts showing revenue slowing to low single‑digit growth by 2026 and downward‑trending forward EPS. Offsets cited (Medicare coverage, tariff exemptions, potential oral Wegovy approval) are judged insufficient, though international obesity care is growing (+83%) and Wegovy sales are up 168%; management plans 9,000 layoffs targeting DKK 8 billion in annualized savings.

Analysis

Market structure: Winners are lower-cost GLP-1 entrants, PBMs/insurers and Eli Lilly (LLY) gaining share via cost-competitive offerings; losers are Novo Nordisk (NVO) and high-ASP branded obesity models as US net price floors move toward $150–$245/month by 2027. Competitive dynamics will shift from margin-led growth to volume-led share battles — expect NVO global volume to rise but US ASPs to compress, moving implied forward EPS down from current 13x multiple assumptions within 12–24 months.

Risk assessment: Tail risks include accelerated regulatory pricing (TrumpRx implementation within 6–12 months), an FDA approval of cheap oral GLP‑1s earlier than 2027, or aggressive PBM rebates that force >20–30% ASP declines; currency (DKK) weakness could magnify reported EPS hits. Immediate effects (days) are volatility spikes on policy headlines, short-term (3–12 months) are EPS revisions and guidance cuts, long-term (2026+) are structurally lower margin profile unless DKK8B cost saves and international growth offset US losses.

Trade implications: Tactical short NVO exposure via 6–12 month put spreads (defined risk) sized 1.5–2% portfolio; pair trade long LLY (1.5–2%) vs short NVO (1.5–2%) to capture relative EPS momentum. Use 3–6 month NVO 10% OTM put spreads sold against 2–3 month OTM call credit (collar) if funding cost is attractive; rotate proceeds into diversified big pharm (JNJ, LLY) and healthcare services (HCA) over 3–9 months.

Contrarian angles: Consensus underweights NVO’s international momentum (obesity +83%, Wegovy +168%) and the DKK8B cost program — a >25% pullback could be a tactical buying opportunity. Consider a small, event-driven long (0.5–1% portfolio) funded by short-dated volatility if forward EPS revisions stabilize and FDA/CMS signals remain neutral for 90–180 days; beware of short-squeeze risk if competition timelines slip.

Key Decisions for Investors

• Establish a 1.5–2.0% portfolio short in NVO via 6–12 month put spread (buy 6–12m 10% OTM put, sell 6–12m 20–25% OTM put) to limit capital at risk; exit or reassess if NVO cuts guidance by <5% or if share falls >30% from entry.
• Implement a pair trade: long LLY 1.5–2.0% vs short NVO 1.5–2.0% (equal notional) to exploit relative growth divergence; hold 6–12 months, trim if LLY misses guidance or NVO announces >DKK4B incremental cost savings earlier than expected.
• Buy a defensive collar on NVO for a tactical hedge: purchase 3–6 month 10% OTM puts funded by selling 3 month 15–20% OTM calls sized to keep net cost ~0; use if holding NVO exposure into policy/catalyst windows (next 30–90 days).
• Reduce overweight positions in pure-play obesity/GLP-1 names by 20–40% and rotate proceeds into diversified large-cap pharma (e.g., JNJ, LLY) and healthcare services (HCA) over the next 30–90 days to lower ASP/pricing exposure.
• Monitor three catalysts over the next 30–180 days and treat as trade triggers: (1) CMS/Medicare coverage announcement (30–90d), (2) any federal pricing law progress (TrumpRx timeline within 180d), (3) FDA signals on oral GLP‑1 approvals (PDUFA/advisory within 90–180d).